INTRODUCTION
Coumarins are the important class of heterocyclic compounds and have gained considerable synthetic and pharmacological interest for a long time because of their various biological activities,1-5 such as antihelminitic, anti-HIV activity, antioxidation. Several nitrogen mustards synthesized from 6-amino coumarin are reported as antiviral agents and especially effective against HIV.6 Several physiological activities of various thiazole derivatives have proved the efficancy in combating various diseases, and have good antibacterial and antifungal activities,7,8 it has been observed that thiazole analogues incorporated with different nuclei have shown variety of pharmacological profiles such as anticancer,9 antifungal10 activities. Although various thiazolopyrimidones are known in literature for their pharmacological activites11 but only few multi step pathway for its preparation are known which tedious and time consuming. Furthermore thiazole and coumarin derivatives with heterocyclic system at position 3 and 6 of benzopyran moiety have shown some promising biological activity.12 By observing the biological importance of the above heterocycles, we thought to incorporate thiazolopyrimidones moiety on coumarin nucleus and scan for their antimicrobial activity.
In continuation of our earlier work on synthesis of heterocyclic systems derived from 6-amino-coumarin. We here report an alternative synthetic pathway for synthesis of thiazolopyrimidinone derivatives under milder condition by cyclocondensation reaction on a pre-existing 6-(2-amino-1,3-thiazole-4-yl)amino-coumarin13 with EAA in a mixture of POCl3 and PPA to give 7-methyl-3-(2ᐟ-oxo-2H-benzopyran-6ᐟ-yl)-5H-1,4-thiazolo-[3,2-a]pyrimidin-5-one 2a-c in one step process Scheme 1.
Scheme 1
However ring closure does not proceed in POCl3 or PPA alone. This mixed reagent had also been used for the preparation several nitrogen bridged systems. Hence by seeing the biological activities of above heterocycles, we here report the synthesis of thiazolo-pyrimidinone derivatives using POCl3 and PPA as mixed reagent and then screen for their antimicrobial activity.
RESULTS AND DISCUSSION
Reaction of 6-(2-Chloro-acetyl)-amino-coumarin with thiourea resulted in the formation of 6-(2-amino-1,3-thiazole-4-yl)amino-coumarin13 1a-c. Condensation of 1a-c with EAA gave the corresponding schiffs base 6-[2-(2ᐟ-oxo-2H-benzopyran-6ᐟ-yl-)1,3-thiazolo-2-yl] imino-butyric acid ethyl ester 3a-c. The IR spectra of compound 3c shows prominent peaks at 1618 cm-1 (-C=N), 1715 cm-1 (C=O) and 1735 cm-1 (COOEt). In its 1H NMR it shows signals as triplet for CH3 protons at δ 1.13 and a quartet at δ 4.20 for methylene protons. It also shows a singlet at δ 2.30 for three protons of –N=C-CH3 along with the other signals. Compound 3a-c on cyclization with a mixture of PPA and POCl3 gave the 7-methyl-3-(2ᐟ-oxo-2HBenzopyran-6ᐟ-yl)-5H-1,4-thiazolo-[3,2-a]pyrimidin-5-one 2a-c. This is two step process Scheme 2.
IR spectrum in KBr of compound 2c shows a peak at 1676 cm-1 for carbonyl of pyrimidine and a peak at 1721cm-1 for carbonyl carbon of coumarin stretch. In its 1H NMR it shows a singlet at δ 6.28 for one protons of -CH=C. It also showed absence of signals for methyl protons and methylene protons which were observed in compound 3a-c as a triplet and quartet indicating the formation of product.
Scheme 2
Anti-microbial activity
All compounds have been screened for their antimicrobial activity and have found to exhibit significant biological activity (Table 1). The compounds 2a-c and 3a-c were screened for their antibacterial activity against Bacillus subtilis, Escherichia coli. and antifungal activity against Candida albicans, Aspergillus Niger by cup plate method at different concentrations (100 and 250 ppm) using DMSO as solvent. The zone of inhibition of the growth was measured in mm. The activity was compared with the standard drugs. A commercial antibacterial Streptomycin (100, 250 μg/mL) and antifungal Griseofulvin (100, 250 μg/mL) drug was also tested under similar conditions for comparison.
From the antimicrobial screening of the compounds (2a-c), (3a-c) it could observe that the pyrimidinones derivatives 2a-c show significant antimicrobial activity.
EXPERIMENTAL
Melting points were taken in open capillaries and were uncorrected. IR spectra (νmax in cm-1) were recorded on Perkin Elmer FTIR and NMR (1H and 13C) was recorded on Jeol 300 MHz using TMS as standard. Mass spectra (GC-MS) on a Shimadzu GC-MS QP-2010. All products are purified by recrystallisation. The reaction are followed up and purity of the products is carried out on pre-coated TLC plates (Silica gel 60 F254, Merck), visualizing the sports in ultraviolet light. All the compounds gave satisfactory elemental analysis.
Preparation of 7-methyl-3-(2ᐟ-oxo-2H-Benzopyran-6ᐟ-yl)-5H-1,4-thiazolo-[3,2-a]pyrimidin-5-one 2a-c (Scheme 1)
Table 1.Sm = Streptomycin, Zone of inhibition diameter in mm: (-) < 8, (+) 8-10, (+ +) 10-16, (+ + +) 16-22, (+ + + +) 22-27. Gf = Griseofulvin, Zone of inhibition diameter in mm: (-) < 7, (+) 7-10, (+ +) 12-18, (+ + +) 18-22, (+ + + +) 22-28.
A mixture 6-(2-amino-1,3-thiazole-4-yl)amino-coumarin 1a-c (0.01 mol) and ethyl acetoacetate (0.01 mol) was suspended in POCl3 (0.03 mol) at r t. To this mixture freshly prepared polyphosphoric acid (0.003 mol) was added. The reaction mixture was refluxed on an oil bath at 90 ℃ for 3 to 4 hr till HCl evolution subsides. The reaction mixture was cooled and poured into crushed ice, the solid obtained was washed with 5% aqueous NaHCO3 solution and with water and recrystallized from methanol to give 2a-c.
(2a): Mol. Formula: C16H11O3N3S, m.p 223 ℃, Yield 62%, IR (cm-1) 3250 (-NH), 3050 (CH-arom), 1718 (C=O), 1686 (C=O, pyrimidone), 1170 (C-N). 1H-NMR (CDCl3): 2.39 (s, 3H, C7-CH3), 6.25 (d, 1H, J = 9 Hz, C3ᐟ-H), 6.29 (s, 1H, C6-H), 6.68 (s, 1H, CH-thiazole), 6.92 (d, 1H, J = 9.0 Hz, C7ᐟ-H), 7.05 (d, 1H, J = 9.0 Hz, C8ᐟ-H), 7.10 (s, 1H, C5ᐟ-H), 7.84 (d, 1H, J = 9.0 Hz, C4ᐟ-H), 9.40 (s, 1H, NH, D2O-exchangable). Elemental analysis [Cal. (Obs.)]: C; 59.07% (59.23%), H; 3.41% (3.48%), N; 12.92% (12.99%), S; 9.86% (9.90%).
(2b): Mol. Formula: C17H13O3N3S, m.p 220 ℃, Yield 58%, IR (cm-1) 3192 (-NH), 2950 (CH-arom), 1718 (C=O), 1680 (C=O, pyrimidone), 1175 (C-N). 1H-NMR (CDCl3): 2.28 (s, 3H, C7ᐟ-CH3), 2.40 (s, 3H, C7-CH3), 6.20 (d, 1H, J = 9.3 Hz, C3ᐟ-H), 6.33 (s, 1H, C6-H), 6.70 (s, 1H, CH-thiazole), 7.08 (s, 1H, C8-H), 7.15 (s, 1H, C5-H), 7.80 (d, 1H, J = 9.0 Hz, C4ᐟ-H), 9.40 (s, 1H, NH, D2O-exchangable). Elemental analysis [Cal. (Obs.)]: C; 60.17% (59.33%), H; 3.86% (3.89%), N; 12.38% (12.45%), S; 9.45% (9.37%).
(2c): Mol. Formula: C18H15O3N3S, m.p 225 ℃, Yield 52%, IR (cm-1) 3230 (-NH), 2945 (CH-arom), 1721 (C=O), 1676 (C=O, pyrimidine), 1172 (C-N). 1H-NMR (CDCl3): 2.30 (s, 3H, C7ᐟ-CH3), 2.36 (s, 3H, C7-CH3), 2.45 (s, 3H, C4ᐟ-CH3), 6.20 (s, 1H, C3ᐟ-H), 6.28 (s, 1H, C6-H), 6.76 (s, 1H, CH-thiazole), 7.10 (s, 1H, C8-H), 7.29 (s, 1H, C5-H), 9.35 (s, 1H, NH, D2O-exchangable). 13C NMR (300 MHz, CDCl3): δ 16.5 (C7ᐟ-CH3), 18.9 (C4ᐟ-CH3), 22.3 (CH3), 104.2 (C2), 107.2 (C6), 112.2-140.5 (7-aromatic-C), 150.3 (C8ᐟa), 153.0 (C4ᐟ), 155 (C7) 158.0(CO), 160.8 (C2ᐟ-C=O), 161.0 (S-C=N). MS m/z (%) : M+ 353, 325, 310, 282, 277, 252 (100), 251, 245, 188, 179, 165, 159, 145, 137, 120, 117, 116, 97, 91, 87, 72, 45. Elemental analysis [Cal. (Obs.)]: C; 61.18% (61.42%), H; 4.28% (4.30%), N; 11.89% (11.75%), S; 9.07% (9.14%).
Preparation of 6-[2-(2ᐟ-oxo-2H-benzopyran-6ᐟ-yl)-1,3-thiazolo-2-yl]imino-butyric acid ethyl ester 3a-c
A mixture 6-(2-amino-1,3-thiazole-4-yl)amino-coumarin 1a-c (1 mmol) and EAA (5 mL) was taken. The reaction mixture was refluxed on an oil bath for 6 - 8 hr, at 140 ℃. The reaction mixture was cooled to r.t, the solid separated was filtered, dried and recrystallised from methanol to give 3a-c.
(3a): Mol. Formula: C18H17O4N3S, m.p 188 ℃, Yield 60%, IR (cm-1) 3236 (-NH), 3050 (CH-arom.), 1735 (COOEt), 1718 (CO), 1554 (-C=C), 1610 (-C=N). 1H-NMR (CDCl3): 1.14 (t, 3H, CH2-CH3), 2.21 (s, 3H, -N=C-CH3), 4.19 (q, 2H, CH2-CH3), 3.50 (s, 2H, CH2), 6.21 (d, 1H, J = 9 Hz, C3ᐟ-H), 6.89-7.20 (m, 4H, Arom-H), 7.80 (d, 1H, J = 9 Hz, C4ᐟ-H), 9.50 (s, 1H, NH, D2O-exchangable). Elemental analysis [Cal. (Obs.)]: C; 58.21% (58.48%), H; 4.61% (4.65%), N; 11.31% (11.39%), S; 8.63% (8.54%).
(3b): Mol. Formula: C19H19O4N3S, m.p 198 ℃, Yield 56%, IR (cm-1) 3231 (-NH), 3042 (CH-arom.), 1730 (COOEt), 1720 (CO), 1550 (-C=C), 1611 (-C=N). 1H-NMR (CDCl3): 1.13 (t, 3H, CH2-CH3), 2.28 (s, 3H, -N=C-CH3), 2.32 (s, 3H, C7ᐟ-CH3), 4.18 (q, 2H, CH2-CH3), 3.45 (s, 2H, CH2), 6.21 (d, 1H, J = 9 Hz, C3ᐟ-H), 6.92-7.21 (m, 3H, Arom-H), 7.82 (d, 1H, J = 9 Hz, C4-H), 9.45 (s, 1H, NH, D2O-exchangable). Elemental analysis [Cal. (Obs.)]: C; 59.21% (59.50%), H; 4.97% (5.02.%), N; 10.90% (10.98%), S; 8.32% (8.25%).
(3c): Mol. Formula: C20H19O4N3S, m.p 194 ℃, Yield 50%, IR (cm-1) 3231 (-NH), 3042 (CH-arom.), 1735 (COOEt), 1715 (CO), 1550 (-C=C), 1618 (-C=N). 1H-NMR (CDCl3): 1.14 (t, 3H, CH2-CH3), 2.21 (s, 3H, C7ᐟ-CH3), 2.30 (s, 3H, -N=C-CH3), 2.40 (s, 3H, C4ᐟ-CH3), 4.20 (q, 2H, CH2-CH3), 3.45 (s, 2H, CH2), 6.21 (s, 1H, C3ᐟ-H), 7.02-7.30 (m, 3H, Arom-H), 9.50 (s, 1H, NH, D2O-exchangable). 13C NMR (300 MHz, CDCl3): δ 14.8 (CH3 of ethoxy), 17.0 (C7ᐟ-CH3), 19.0 (C4ᐟ-CH3), 21.0 (CH3), 43.0 (CH2), 60.20 (CH2 of ethoxy), 104.4 (C5), 112.2-140.2 (7-aromatic-C), 152.0 (C8ᐟa), 154.0 (C4ᐟ), 160.0(C2ᐟ-C=O), 161.0 (C=O of ester), 165.0 (CH3-C=N), 168.0 (C2). MS m/z (%): M+ 399, 368, 367,340, 326, 311(100), 285, 283, 215, 210, 185, 184, 181, 175, 174, 153, 114, 101, 96, 91, 89, 77, 72, 65. Elemental analysis [Cal. (Obs.)]: C; 60.15% (60.34%), H; 5.26% (5.30%), N; 10.52% (10.61%), S; 8.02% (8.15%).
Preparation of 7-methyl-3-(2ᐟ-oxo-2H-Benzopyran-6ᐟ-yl)-5H-1,4-thiazolo-[3,2-a]pyrimidin-5-one. 2a-c (Scheme 2)
A mixture 6-[2-(2ᐟ-oxo-2H-benzopyran-6ᐟ-yl)-1,3-thiazolo-2-yl]imino-butyric acid ethyl ester 3a-c (0.01 mol) was suspended in POCl3 (0.03 mol) at r t. To this mixture freshly prepared polyphosphoric acid (0.003 mol) was added. The reaction mixture was refluxed on an oil bath at 90 ℃ for 3 hr till HCl evolution subsides.The reaction mixture was cooled and poured into crushed ice, the solid obtained was washed with 5% aqueous NaHCO3 solution and with water and recrystallized from methanol to give 2a-c.
Antimicrobial activity
The Cup plate method using Hi-Media agar medium was employed to study the antibacterial activity of compounds 2a-c & 3a-c against Bacillus subtilis, Escherichia coli. Preparation of nutrient broth, subculture, base layer medium, agar medium and peptone water was done as per the standard procedure.14 Sample size for all the compounds was fixed at 0.1 mL. Using a sterilized cork borer cups were scooped out of agar medium contained in a petri dish which was previously inoculated with the microorganisms. The test compound solution (0.1 mL) was added in the cups and the petri dishes were subsequently incubated at 37 ℃ for 24 h. Streptomycin were used as reference drugs and DMSO as control. Zones of inhibition produced by each compound was measured in mm, and the results are listed in Table 1.
The antifungal activities of compounds 2a-c and 3a-c were tested against Candida albicans, Aspergillus niger by agar diffusion method.15
References
- Thitima, P.; Muney, S.; Stephen, H. H.; Djaja, D. S.; John, M. P. J. Nat. Prod. 1996, 59, 839 https://doi.org/10.1021/np960399y
- Ptail, A. D.; Freyer, A. J.; Drake, S. E.; Haltiwanger, R. C.; Bean, M. F.; Taylor, P. B.; Caranfa, M. J.; Breen, A. L.; Bartus, H. R.; Johnson, R. K.; Hertzberg, R. P.; Westley, J. W. J. Med. Chem. 1993, 36, 4131. https://doi.org/10.1021/jm00078a001
- Zhao, H.; Neamati, N.; Hong, H. X.; Mazumder, A.; Wang, S. M.; Sunder, S.; Milne, G. W. A.; Pommier, Y.; Burke, T. B. J. Med. Chem. 1997, 40, 242. https://doi.org/10.1021/jm960450v
- Yun, B. S.; Lee, I. K.; Ryoo, I. J.; Yoo, I. D. J. Nat. Prod. 2001, 64, 1238. https://doi.org/10.1021/np0100946
- Badran, M. M.; Ismail, M. M.; El-Hakeem, M. A. Egypt. J. Pharm. Sci. 1992, 33, 1081.
- El-Farargy, A. F. Egypt J. Pharm. Sci. 1991, 32, 625.
- Tunek, H. Monatsh. 1962, 93, 684. https://doi.org/10.1007/BF01189608
- Nofal, Z. M.; El-Masry, A. H.; Fahmy, H. H.; Sarhan, A. I. Egypt. J. Pharm. Sci. 1997, 38, 1.
- Kun, E.; Aurelian, L.; U S Pat. 1991, 412783; C. A: 1991, 113, 92071t.
- Phanekar, D. Y.; Ghiya, B. J. Ind. J. Het. Chem. 1995, 5, 159.
- Rasup, C.; Sup, Y. R.; Woo, B. C. Korean J. Med. Chem. 1995, 5, 72.
- Srimant, K.; Rajeshwar, R. V.; Krishna Arzneim, D. R. Forsch Drug Res. 2002, 52, 388.
- Pattan, S. R.; Narendra Babu, S. N.; Angadi, J. S. Indian drugs. 2002, 39(10), 388.
- Fawzy A Allahy, Sanna M. Eldin. Z. Naturforsch. 1999, 54b,788-798.
- Rajeswar Rao, V.; Ravinder Reddy, V. Chem. Het. Compound 2008, 44, 3.
- Kumar, P. V.; Manoher, R. K.; Rajeshwar, R. V. Ind. J. Chem. 2008, 47B, 759.
- Mulwad, V. V; Mir, A. A. J. Chem. Res. 2008, May, 292.
- British Pharmacopoeia. 2005, Vol. IV, Appendix XIV, p A300
- Holt, R. J. J. Clin. Path. 1975, 28, 767-774. https://doi.org/10.1136/jcp.28.10.767
Cited by
- Crystal structures of two 6-(2-hydroxybenzoyl)-5H-thiazolo[3,2-a]pyrimidin-5-ones vol.71, pp.7, 2015, https://doi.org/10.1107/S2056989015011044